

Misetionamide (GP-2250) Publications Summary

2025

1. Panavance Therapeutics Presents Promising Misetionamide (GP-2250) Phase 1 Clinical Trial Interim Findings in Pancreatic Cancer at BIO 2025. Press Release. June 13, 2025. <https://panavance.com/press/panavance-therapeutics-announces-promising-misetionamide-gp-2250-phase-1-clinical-trial-interim-findings-in-pancreatic-cancer-at-bio-2025/>
2. Kasi A, Iglesias, JL. Interim Open-Label Phase 1 Results of Misetionamide (GP-2250): A Small Molecule Antineoplastic That Inhibits Three Major Transcription Factors. ASCO 2025 Poster. <https://panavance.com/wp-content/uploads/2025/05/asco-2025-kasi-et-al-interim-open-label-phase-1-results-of-misetionamide-gp-2250.pdf>

2024

3. Panavance Announces New Discovery that Misetionamide Directly Inhibits Oncogenic Transcription Factor **c-MYC**. New finding builds upon previous confirmation of misetionamide's direct inhibition of NFkB. Direct targeting of these two transcription factors inhibits multiple downstream signaling pathways in cancer cells. New data was presented at the October Visceral Medicine Congress in Leipzig, Germany. November 19, 2024. <https://panavance.com/press/panavance-announces-new-discovery-that-misetionamide-directly-inhibits-oncogenic-transcription-factor-c-myc/>
4. Mark Kim, Deanna Glassman, Katelyn F Handley, Adrian Lankenau ahumada, Emine Bayraktar, Nicholas B. Jennings, Robiya Joseph, Robert L. Coleman and Anil K. Sood. Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in **ovarian cancer**. Cancer Medicine. 2024. <http://panavance.com/wp-content/uploads/2024/08/2024-Cancer-Medicine-Kim-et-al-Mechanisms-and-rational-combinations-with-GP-2250-novel-oxathiazine-derivative-in-ovarian-cancer.pdf>
5. R Duane Sofia, PhD, Kathryn M Martin, PharmD, James C Costin, MD. Antineoplastic Activity of GP-2250 in Vitro and in Mouse Xenograft Models. Anti-Cancer Drugs 2024, 35:183–1899. <https://panavance.com/wp-content/uploads/2024/02/Sofia-RD.2024.Anti-Cancer-Drugs.pdf>
6. I. Peters; B. Majchrzak-Stiller; M. Buchholz; P. Höhn; W. Uhl; C. Braumann; J. Strotmann. Increasing the **cytotoxic effectivity of 5FU, Irinotecan and Oxaliplatin** on pancreatic cancer cells through combination with the novel anticancer agent GP-2250 in vitro (conference paper: Oncol Res Treat 2024;47(suppl 1):7–283, abstract 776).

Misetionamide (GP-2250) Publications Summary

<https://panavance.com/wp-content/uploads/2024/04/Oncol-Res-Treat-2024-Peters-I-et-al.-Cytotoxic-effectivity-of-5FU-Irinotecan-and-Oxaliplatin.pdf>

2023

7. Majchrzak-Stiller B, Buchholz M, Peters I, Waschestjuk D, Strotmann J, Höhn P, Hahn S, Braumann C, Uhl W, Müller T, Möhler H. GP-2250, a novel anticancer agent, **inhibits the energy metabolism**, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells. J Cell Mol Med. 2023 Jul;27(14):2082-2092. doi: 10.1111/jcmm.17825. Epub 2023 Jun 30. <https://panavance.com/wp-content/uploads/2023/09/J-Cellular-Molecular-Medi-2023-Majchrzak-Stiller.pdf>
8. Majchrzak-Stiller B, Buchholz M, Peters I, Strotmann J, Möhrke J, Zelichowski L, Oehlke L, Quensel C, Fein D, Höhn P, Müller T, Uhl W, Braumann C. Oxathiazinane derivatives display both antineoplastic and antibacterial activity: a structure activity study. J Cancer Res Clin Oncol. 2023 Sep;149(11):9071-9083. doi: 10.1007/s00432-023-04799-8. Epub 2023 May 12. <https://link.springer.com/content/pdf/10.1007/s00432-023-04799-8.pdf>
9. Barras M, Schmitz L, Braumann C, Uhl W, Skyrman M, Buchholz M, Meyer T, Stockfleth E, Müller T, Becker JC, Gambichler T. An in vitro pilot study investigating the antineoplastic effects of GP-2250 on **cutaneous squamous cell carcinoma** cell lines: preliminary results. Dermato. 2023; 3:85-86. <https://panavance.com/wp-content/uploads/2023/09/dermato-03-00007.pdf>
10. Gambichler T, Majchrak-Stiller B, Peters I, Becker JC, Müller T, Uhl W, Abu Rached N, Buchholz M, Braumann C. The effect of GP-2250 on virus-negative **Merkel cell carcinoma** cell lines: preliminary results. J Cancer Res Clin Oncol. 2023 Jun 14. doi: 10.1007/s00432-023-04960-3. <https://pubmed.ncbi.nlm.nih.gov/37311987/>
11. Thilo Gambichler, Friederike Harnischfeger, Marina Skrygan, Britta Majchrzak-Stiller, Marie Buchholz, Thomas Müller, and Chris Braumann. In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated **Melanoma Cell Lines** and Benign Melanocytes. Int. J. Med. Sci. 2023, 24, 15336. <https://panavance.com/wp-content/uploads/2023/11/Gambichler-T.-et-al.-Int.-J.-Mol.-Sci. 24 2023.pdf>
12. Mark S. Kim¹, Deanna Glassman¹, Adrian Lankenau Ahumada¹, Emine Bayraktar¹, Nicolas B. Jennings¹, Robiya Joseph¹, Sanghoon Lee¹, Robert L. Coleman², Anil K. Sood¹. Mechanisms and rational combinations with GP-2250, a novel oxathiazine derivative, in **ovarian cancer**. AACR 2023 Poster. https://panavance.com/wp-content/uploads/2023/04/2023-AACR-Abstract_OlandoFL_MKIM_Final.pdf

2022

Misetionamide (GP-2250) Publications Summary

13. Baron C, Buchholz M, Majchrzak-Stiller B, Peters I, Fein D, Müller T, Uhl W, Hühn P, Strotmann J, Braumann C. Substance GP-2250 as a new therapeutic agent for **malignant peritoneal mesothelioma** - a 3-D in vitro study. Int J Mol Sci. 2022;23(13):7923. <https://panavance.com/wp-content/uploads/2023/09/ijms-23-07293.pdf>
14. Kasi A, Iglesias, JL. **A Phase 1/2 Trial of GP-2250** in Combination with Gemcitabine in Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with FOLFIRINOX Chemotherapy. Poster TPS620 presented at the 2022 ASCO GI Cancers Symposium. https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.TPS620
15. Buchholz M, Strotmann J, Majchrzak-Stiller B, Hahn S, Peters I, Horn J, Müller T, Höhn P, Uhl W, Braumann C. New Therapy Options for Neuroendocrine Carcinoma of the Pancreas - The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the **Development of Secondary Resistances** In Vitro and In Vivo. Cancers 2022;14:2865. <https://panavance.com/wp-content/uploads/2022/06/cancers-14-02685-v2.pdf>

2020

16. Braumann C, Buchholz M, Majchrzak-Stiller B, Hahn S, Uhl W, Kasi A, Mueller T. **Metabolism-based GP-2250 in combination with gemcitabine** as a novel approach to pancreatic cancer: A mouse xenograft study. Journal of Clinical Oncology 2020 38:15_suppl, e16750-e16750. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e16750

2017

17. Buchholz M, Majchrzak-Stiller B, Hahn S, Vangala D, Pfirrmann R, Uhl W, Braumann C, Chromik AM. Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant **pancreatic carcinoma - in vitro and in vivo**. BMC Cancer. 2017;17(1). <https://pubmed.ncbi.nlm.nih.gov/28340556/>

2016

18. Majchrzak-Stiller B, Buchholz M, Vangala D, Hahn S, Pfirrmann R, Chromik Am, Braumann C, Uhl W. ID 0140: Taurolidine, substance 2250 and not gemcitabine displays antineoplastic activity on **pancreatic stem-cell** like multicellular spheroid cultures. Oncol Res Treat. 2016;39 (Suppl 1), Abstract 140. https://panavance.com/wp-content/uploads/2022/05/Buchholz-ID-0144_OncolResTreat_15_2016.pdf